Long-term safety follow-up for wet AMD treatment
Treatments studied
Part of Eyes & vision clinical trials.
This study is a follow-up for people who have already received an injection of RGX-314 for wet age-related macular degeneration (AMD) in an earlier trial. It looks at how the treatment works over a longer time and any long-term effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have taken part in a previous RGX-314 study for wet AMD
- You must have received the RGX-314 injection in that earlier study
- You must agree to follow the study rules and sign a consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new injection called RBS-001 compared to the standard treatment Eylea for wet age-related macular degeneration (AMD). The goal is to see if the new drug is as safe and effective at improving vision by reducing fluid and blood vessel growth in the eye.
This study follows people who completed an earlier 2-year trial of OTX-TKI, a small implant placed in the eye to treat wet age-related macular degeneration (a condition causing vision loss). Researchers want to make sure the treatment remains safe over time.
This trial tests a new CRISPR-based treatment for wet age-related macular degeneration (AMD). It aims to stop vision loss by targeting the cause of abnormal blood vessel growth in the eye. This study is for people who have already tried anti-VEGF injections but might not be responding well enough.
This study checks how well a previous eye treatment (RGX-314) lasts over time. There is also an extra “other eye” study for people with age-related macular degeneration affecting both eyes.
This study follows people who already received an injection of RGX-314 (an experimental gene therapy) in a previous clinical trial for diabetic retinopathy, with or without swelling in the macula. It checks the long-term safety and how the treatment works over time.
This trial tests a one-time gene therapy injection for wet AMD that may reduce the need for regular eye injections. It is for people who have already responded to anti-VEGF injections but want a longer-lasting treatment.
Hear when a new Neovascular Age-Related Macular Degeneration (nAMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.